Gary L. Buchschacher

4.6k total citations · 1 hit paper
42 papers, 1.2k citations indexed

About

Gary L. Buchschacher is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gary L. Buchschacher has authored 42 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Gary L. Buchschacher's work include Virus-based gene therapy research (11 papers), CRISPR and Genetic Engineering (9 papers) and HIV Research and Treatment (6 papers). Gary L. Buchschacher is often cited by papers focused on Virus-based gene therapy research (11 papers), CRISPR and Genetic Engineering (9 papers) and HIV Research and Treatment (6 papers). Gary L. Buchschacher collaborates with scholars based in United States, Japan and Spain. Gary L. Buchschacher's co-authors include Antonito T. Panganiban, Flossie Wong‐Staal, Eric O. Freed, Eric Delwart, Nobuaki Matsubara, Christopher J. Sweeney, Charles G. Drake, Karim Fizazi, Edward E. Kadel and Kobe Yuen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Nature Medicine.

In The Last Decade

Gary L. Buchschacher

42 papers receiving 1.2k citations

Hit Papers

Atezolizumab with enzalut... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
    2022 157 citations Thomas Powles, Kobe Yuen et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary L. Buchschacher United States 17 588 370 348 342 254 42 1.2k
Edward J. Dunphy United States 16 625 1.1× 353 1.0× 483 1.4× 266 0.8× 208 0.8× 18 1.4k
M Kuppuswamy United States 18 766 1.3× 525 1.4× 232 0.7× 217 0.6× 71 0.3× 27 1.5k
Alagarsamy Srinivasan United States 19 766 1.3× 202 0.5× 256 0.7× 660 1.9× 108 0.4× 55 1.6k
Y. Ramanathan United States 11 1.1k 1.8× 90 0.2× 292 0.8× 365 1.1× 121 0.5× 13 1.5k
Lela Lackey United States 14 1.1k 1.9× 170 0.5× 282 0.8× 452 1.3× 71 0.3× 21 1.6k
Xue F. Huang United States 20 710 1.2× 289 0.8× 587 1.7× 87 0.3× 246 1.0× 34 1.6k
Dorothy L. Buchhagen United States 17 702 1.2× 311 0.8× 643 1.8× 85 0.2× 156 0.6× 26 1.4k
S G Devare United States 19 594 1.0× 475 1.3× 164 0.5× 203 0.6× 39 0.2× 25 1.3k

Countries citing papers authored by Gary L. Buchschacher

Since Specialization
Citations

This map shows the geographic impact of Gary L. Buchschacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary L. Buchschacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary L. Buchschacher more than expected).

Fields of papers citing papers by Gary L. Buchschacher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary L. Buchschacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary L. Buchschacher. The network helps show where Gary L. Buchschacher may publish in the future.

Co-authorship network of co-authors of Gary L. Buchschacher

This figure shows the co-authorship network connecting the top 25 collaborators of Gary L. Buchschacher. A scholar is included among the top collaborators of Gary L. Buchschacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary L. Buchschacher. Gary L. Buchschacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saad, Fred, Andrew J. Armstrong, Karina Vianna, et al.. (2024). Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial. European Urology Oncology. 7(6). 1394–1402. 7 indexed citations
2.
Stearns, Vered, Opeyemi A. Jegede, Victor T. Chang, et al.. (2024). A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11. Clinical Cancer Research. 30(13). 2709–2718. 4 indexed citations
3.
4.
Cho, Byoung Chul, Chao‐Hua Chiu, Erminia Massarelli, et al.. (2023). Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. Lung Cancer. 188. 107442–107442. 19 indexed citations
5.
Metges, Jean‐Philippe, Ken Kato, Jong‐Mu Sun, et al.. (2022). First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.. Journal of Clinical Oncology. 40(4_suppl). 241–241. 16 indexed citations
6.
Powles, Thomas, Kobe Yuen, Silke Gillessen, et al.. (2022). Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine. 28(1). 144–153. 157 indexed citations breakdown →
7.
Eng, Cathy, Emerson Y. Chen, Jane E. Rogers, et al.. (2021). Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncology Practice. 17(10). 607–614. 6 indexed citations
8.
Sweeney, Christopher J., Silke Gillessen, Dana E. Rathkopf, et al.. (2020). Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Research. 80(16_Supplement). CT014–CT014. 47 indexed citations
9.
Conley, Anthony P., George D. Demetri, Robert C. Doebele, et al.. (2020). 539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study. Annals of Oncology. 31. S471–S472. 2 indexed citations
10.
Bono, Johann S. de, Sergio Bracarda, Cora N. Sternberg, et al.. (2020). LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 31. S1153–S1154. 22 indexed citations
11.
12.
13.
14.
Lu, Sharon, et al.. (2016). Concurrent Radiotherapy and Triweekly Carboplatin for the Definitive Treatment of Locally Advanced Laryngeal Carcinoma. American Journal of Clinical Oncology. 41(6). 595–600. 2 indexed citations
15.
16.
Buchschacher, Gary L.. (2001). Introduction to retroviruses and retroviral vectors.. Somatic Cell and Molecular Genetics. 26(1/6). 1–11. 30 indexed citations
17.
Buchschacher, Gary L. & Flossie Wong‐Staal. (2000). Development of lentiviral vectors for gene therapy for human diseases. Blood. 95(8). 2499–2504. 61 indexed citations
18.
Buchschacher, Gary L., et al.. (1992). Analysis of HIV-1 Envelope Mutants and Pseudotyping of Replication-Defective HIV-1 Vectors by Genetic Complementation. AIDS Research and Human Retroviruses. 8(9). 1669–1677. 18 indexed citations
19.
Buchschacher, Gary L., Eric O. Freed, & Antonito T. Panganiban. (1992). Cells Induced to Express a Human Immunodeficiency Virus Type 1 Envelope Gene Mutant Inhibit the Spread of Wild-Type Virus. Human Gene Therapy. 3(4). 391–397. 27 indexed citations
20.
Buchschacher, Gary L., et al.. (1992). Preferential expression of one  -tubulin gene during flagellate development in Physarum. Journal of General Microbiology. 138(1). 229–238. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edward J. Dunphy Breakdown of academic impact, for papers by M Kuppuswamy Breakdown of academic impact, for papers by Alagarsamy Srinivasan Breakdown of academic impact, for papers by Y. Ramanathan Breakdown of academic impact, for papers by Lela Lackey Breakdown of academic impact, for papers by Xue F. Huang Breakdown of academic impact, for papers by Dorothy L. Buchhagen Breakdown of academic impact, for papers by S G Devare
Rankless by CCL
2026